| INTRODUC TI ON
Chronic gastrointestinal (GI) symptoms have multicultural aspects because culture, race, ethnicity, sex/gender, genetics, the microbiome, environmental hygiene, cytokines, and nervous system may affect the generation of symptoms. 1 Chronic constipation (CC) is a typical GI disorder with prevalence reported to be from 1.9% to 27 .2%, with most estimates from 12% to 19% in North America. 2 In Japan, a population weighted random sample of households selected by controlling for the size of cities, towns and villages showed a 2.08% incidence of constipation in a total of 3356 individuals.
Moreover, multivariable regression analyses showed that female gender, older age, number of comorbidities, and a poor mental health component of a general quality of life (QOL) instrument were associated with constipation. 3 Linaclotide, a nonabsorbable peptide, is a novel guanylate cyclase-C (GC-C) receptor agonist. 4 Linaclotide activates GC-C and increases intracellular cyclic guanosine monophosphate (cGMP). 4 This causes secretion of chloride and bicarbonate ions with molecules of water into the intestinal lumen. 4, 5 Earlier studies reported that the optimal dose of linaclotide for North American patients with irritable bowel syndrome with constipation (IBS-C) was 0.29 mg/d, [5] [6] [7] and for patients with CC it was 0.145 mg/d. 8 By contrast, a phase II study of linaclotide in Japan showed that the optimal dose for IBS-C patients was 0.5 mg/d. 9 This finding was supported by a Japanese phase 3 study in which linaclotide was administered at 0.5 mg/d
to IBS-C patients. 10 Therefore, the Pharmaceuticals and Medical
Devices Agency (PMDA) in Japan approved 0.5 mg of linaclotide as the standard clinical dose for IBS-C. However, the optimal dose of linaclotide for Japanese CC patients is unknown.
The scientific importance of performing a dose-finding clinical study of linaclotide in Japanese CC patients is as follows. Studies of a different intestinal secretagogue, lubiprostone, have shown that the optimal doses for CC 11, 12 and IBS-C 13 are different. The clinical dose of lubiprostone for CC is 48 μg/d 11, 12 but for IBS-C it is 16 μg/d. 13 As mentioned above, in the US, the standard doses for IBS-C 5-7 and CC 8 are also different. However, more recent concepts of IBS-C and functional constipation, based on the Rome IV criteria, suggest that these disorders form a spectrum along a continuum, as opposed to being distinct entities. 14 Therefore, we hypothesized that the most likely optimal dose of linaclotide for Japanese patients with CC is the same as that for IBS-C patients (0.5 mg).
| ME THODS

| Patient population
This study was conducted from April 2015 to October 2015 at 50 departments of gastroenterology in Japan hospitals and clinics.
Male and female outpatients aged 20-79 years with CC according to the Rome III functional constipation criteria 15 were eligible.
In brief, patients who experienced fewer than three defecations per week and met at least one of three other criteria of functional constipation 15 (lumpy or hard stools in at least 25% of defecations, sensation of incomplete evacuation for at least 25% of defecations, straining during at least 25% of defecations) for more than six months met the Rome criteria for CC. Because the Rome III criteria exclude IBS-C from functional constipation, no patients with IBS-C were enrolled in this study. 
| Study design
This randomized, double-blind, placebo-controlled, parallel-group, comparative study comprised a screening period, a two-week bowel habit observation period, and a two-week treatment period.
Following the bowel habit observation period, eligible patients were
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randomly assigned to two-week oral treatments with placebo or linaclotide (0.0625 mg, 0.125 mg, 0.25 mg, or 0.5 mg once daily) before breakfast. Randomization was performed in a 1:1:1:1:1 ratio using a web-based randomization system with a block size of five.
All patients, investigators, and sponsors were kept blinded until all observations and evaluations were completed; statistical analysis plans were finalized; and all the data had been entered into the database. Visits were scheduled for week 2 (or at discontinuation) to assess treatment efficacy, drug compliance, and occurrence of adverse events. All the authors had access to the study data and reviewed and approved the final manuscript.
| Data collection
During the bowel habit observation and treatment periods, patients recorded their chronic constipation symptoms every day in a paper diary at bedtime and at each bowel movement, and electronically entered some of these data into the database daily using an interactive voice response system. This system of evaluating symptoms has been shown to be reliable and valid for IBS-C patient studies. and 7, as bad as I can imagine). Disease-specific health-related quality of life was assessed using the IBS-QOL 16 (Japanese version 17 ).
| Efficacy and safety endpoints
The primary endpoint was change in weekly SBM frequency during the first week of the treatment period. Secondary endpoints included SBM responder and complete SBM (CSBM) stool frequency responder, stool consistency (BSFS), severity of abdominal bloating and abdominal pain/discomfort, severity of straining, relief of chronic constipation symptoms, improvement in abnormal bowel habits and abdominal symptoms relief, and improved quality of life (IBS-QOL).
Weekly SBM and CSBM responders were defined as patients with SBM or CSBM of three or more and an increase of one or more from baseline at each weekly evaluation point. Weekly responders for global assessment of relief of CC symptoms, abnormal bowel habits improvement, and abdominal symptoms relief were defined as patients with a score of 1 or 2 at each weekly evaluation point. All adverse events (AEs) were recorded during the treatment period.
| Statistical analysis
Statistical analysis was performed using sas Drug Development (ver. America, using analysis of covariance; multiplicity was adjusted using a closed testing procedure: the higher dose was first compared with placebo and if the difference vs placebo was significant and then lower dose was compared with placebo. The procedure was repeated from high dose to low dose.
In total, 350 patients (70 patients/group) were scheduled for randomization. Efficacy analysis populations included the full analysis set comprising all patients who received at least one dose of the study drug during the treatment period and in whom one or more efficacy endpoints could be evaluated, and the safety analysis set, which consisted of all patients who received at least one dose of the study drug during the treatment period.
To compare the linaclotide groups with placebo, an analysis of covariance was performed with treatment groups as a factor and baseline scores as covariates to measure changes from baseline in weekly mean SBM frequency, CSBM frequency, stool form score, abdominal bloating severity score, abdominal pain/discomfort severity score, straining severity score, the overall IBS-QOL and IBS-QOL subscale scores at each evaluation point during the treatment period. SBM responder, CSBM responder, global assessment of relief responder, abnormal bowel habits improvement responder, and abdominal symptom relief responder were expressed as a percentage of randomized patients with 95% confidence intervals (95% CIs). The treatment groups were compared using Fisher's exact test with a 2-sided significance level of 0.05.
| RE SULTS
| Overall study population
Of the 817 patients who provided written informed consent, 435
failed the screening and 382 were randomly assigned to receive pla- The demographics and baseline characteristics were similar among all the groups with no statistically significant differences ( Efficacy and safety were evaluated in 382 patients.
| Evaluation of the primary endpoint
Change in weekly mean SBM frequency during the first week of the treatment period was 1.91 in the placebo group, and 3.89 
| Evaluation of secondary endpoints
Change in weekly mean CSBM frequency ( Figure 3A) , stool form score ( Figure 3B ), and straining severity score ( Figure 3C ) during Week 1 showed a statistically significant improvement for linaclotide compared to placebo. At Week 2, the change in mean weekly SBM frequency ( Figure 3D ), CSBM frequency ( Figure 3A) , stool form score ( Figure 3B ), and straining severity score ( Figure 3C ) in every linaclotide group was significantly greater than that in the placebo group. Weekly mean SBM frequency ( Figure S1 ), CSBM frequency ( Figure S2 ), stool form score ( Figure S3 ), and straining severity score ( Figure S4 ) in every linaclotide group during Week 1 and 2 were also significantly greater than that in the placebo group.
In the 0.5 mg linaclotide group, the CSBM responder rates at Week 1 and 2 were statistically significantly higher than that in the placebo group ( Figure 4A ). Also in the 0.5 mg linaclotide group, all other responder rates, including SBM ( Figure 4B ), the global assessment of relief of chronic constipation symptoms ( Figure 4C ), improvement of abnormal bowel habits for CC symptoms ( Figure 4D ), and relief of abdominal symptoms for CC symptoms ( Figure 4E ) at Week 1 and 2, were significantly greater than that in the placebo group.
Linaclotide did not significantly improve abdominal bloating, abdominal pain/discomfort or overall IBS-QOL compared with placebo (ANCOVA change from baseline).
| Safety
Adverse events were observed in three (3.8%) patients in the placebo group, and 11 (13.4%), six (8.5%), nine (12.3%), and nine patients (11.8%) in the 0.0625 mg, 0.125 mg, 0.25 mg, and 0.5 mg linaclotide groups, respectively. The incidence of diarrhea, the most commonly reported AE which was expected given the pharmacological action of linaclotide, was significantly higher in the 0.0625 mg (7.3%) and 0.25 mg (8.2%) linaclotide groups compared to the placebo (0.0%) group. There was no significant difference in the incidence of diarrhea in the 0.125 mg (4.2%) or the 0.5 mg (3.9%) linaclotide groups compared to the placebo group (Table 2 ). All the events of diarrhea in this study were rated of mild or moderate severity; there were no cases of severe diarrhea. One patient treated with linaclotide 0.0125 mg reported a linaclotide-related F I G U R E 1 Flowchart of patient progress throughout the study serious adverse event of diarrhea, which resolved after cessation of dosing.
| D ISCUSS I ON
Positive results for the primary endpoint, change from baseline in SBM frequency in the first week of treatment, support the hypothesis of this study. This study confirms our previous findings that linaclotide 0.5 mg/d is an effective and well-tolerated dose for constipated patients in Japan. 9, 10 This dose also produced statistically significant outcomes for change in weekly mean SBM frequency, weekly SBM responder rate, change in weekly mean CSBM frequency, weekly CSBM responder rate, change in weekly mean stool form score, and change in weekly mean straining severity score. These effects began in the first week and they continued through the second week of Data were expressed as mean ± SD, actual numbers, or %. CSBM (complete spontaneous bowel movement); SBM without a sensation of incomplete evacuation, SBM (spontaneous bowel movement); bowel movement without the use of a laxative, suppository, or enema, or taking measures for stool extraction on the day or prior to the day of this bowel movement.
F I G U R E 2 Primary endpoint expressing efficacy of linaclotide. Change in weekly mean SBM frequency during 1 week. Column height: frequency. Error bar: 95% CI. P values derived by analysis of covariance compared to placebo were adjusted by a closed testing procedure from high to low dose treatment. Although all doses of linaclotide were equally effective in terms of the primary endpoint, the CSBM responder which is considered to be an important parameter for assessing the efficacy of drugs for CC in a European Medicines Agency (EMA) guideline, 19 showed the greatest improvement at the 0.5 mg dose during Week 2. In addition, change in stool form score, which we observed a great example of dose response in previous phase II trial for Japanese IBS-C patients, 9 showed the greatest improvement at the 0.5 mg dose during Week 1 and 2 in this trial.
A number of factors support the assumption that 0.5 mg is the most appropriate for the treatment of patients with CC in Japan. has a distinct action that would influence visceral perception. 21 Concerning its action as an intestinal secretagogue, the linaclotide 0.5 mg group showed the greatest changes in BSFS in this study.
Linaclotide activates GC-C expressed on mucosal epithelial cells, resulting in the production and release of cGMP. 21 This extracellular cGMP acted on and inhibited nociceptors and reduced the excitability of neurons in the superficial laminae of the dorsal horn, thereby reducing visceral perception. 21 Evaluation of CSBM, straining, and reported adverse events of diarrhea are all related to visceral perception during defecation. Thus, the results in this study suggest that CC patients who received 0.5 mg of linaclotide felt that defecation was made easier.
The most important scientific finding of this study is that linaclotide 0.5 mg, the highest dose studied, showed the greatest efficacy in Japanese CC patients, which is in contrast with the earlier US studies in CC patients. 8, 18, 22 The approved doses in the US are 0.145 and 0.072 mg/d. The reason a higher dose of linaclotide may be required for Japanese CC patients compared to US CC patients would likely be the same as that for previous studies in IBS-C patients. 9, 10 In brief, the following factors, which differ between Japan and US, may partially explain the different dose requirements. 1, 9, 23, 24 Diet may interfere with digestion of the polypeptide linaclotide. 23 Gut microbiota, especially Bifidobacterium, produce peptidases that may metabolize linaclotide. 25 There are known differences in genetic polymorphism among different populations. 26 The endogenous suggest that CC and IBS-C constitute a single syndrome with a spectrum of symptoms, rather than being distinct disease entities.
Whatever the reason, the appropriate therapeutic dose of linaclotide for patients in Japan is correspondingly higher than that in the US.
This study has some limitations. Foremost, the duration of treatment in this study was shorter (2 weeks) than that (4 weeks) in the phase II dose-ranging study in the US. 18 The design of the current study is similar to that of a previous study of the intestinal secretagogue lubiprostone, also conducted in Japan. 30 Because the duration of treatment of 12 weeks in our IBS-C study demonstrated ongoing improvement of symptoms in the latter phase, 9 a longer duration of treatment in CC patients may show greater benefit.
However, the efficacy of linaclotide appeared quickly and sustained throughout the treatment period in the phase II study 18 and phase III 8 studies in North America. As the symptom of CC is relatively constant, we set 2 weeks as treatment duration in this study.
In conclusion, this study's findings suggest that 0.0625, 0.125, 0.25, and 0.5 mg/d are effective doses of linaclotide for CC patients in Japan.
The best results for CC were seen at 0.5 mg/d, the same dose that elicited the best results for IBS-C. No new safety trends or concerns were identified. Further studies in patients with CC are warranted.
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